PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action
As Illumina runs into another regulatory roadblock to expansion, one of its almost-subsidiaries is charging ahead with a new buyout.
Pacific Biosciences, often referred to as PacBio, is aiming to swallow rival Omniome in an $800 million stock and cash deal, the companies announced Tuesday morning. PacBio will fork over $600 million upfront consisting of $300 million cash and 9.4 million shares, and is on the hook for another $200 million in cash and stock should certain milestones be achieved.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
